store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Setanaxib (GKT137831) 是一种有效的特异性双重 NADPH 氧化酶 (NOX1/4) 抑制剂,Ki 分别为140和110nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 415 | 现货 | ||
2 mg | ¥ 592 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,530 | 现货 | ||
25 mg | ¥ 2,830 | 现货 | ||
50 mg | ¥ 4,220 | 现货 | ||
100 mg | ¥ 5,890 | 现货 | ||
1 g | ¥ 9,820 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 793 | 现货 |
产品描述 | Setanaxib (GKT137831) is a potent, specific dual NADPH oxidase (NOX1/4) inhibitor. |
靶点活性 | NOX4:140 nM(Ki), NOX1:110 nM(Ki) |
体外活性 | 每天给长期低氧环境下的小鼠模型口服60 mg/kg GKT137831,减轻长期缺氧诱导的右心室肥大,血管重塑,肺细胞增殖以及低氧环境下肺PPARγ和TGF-β表达的改变.每天给糖尿病载脂蛋白E不足的小鼠口服60 mg/kg GKT137831可以减弱糖尿病加速的动脉粥样硬化.60 mg/kg i.g. GKT137831阻断WT和SOD1mut小鼠体内肝纤维化,并下调氧化应激,炎症和纤维化的发生.此外,GKT137831在注入angII的 c-hNox4Tg小鼠体内,消除氧化应激的增加,抑制Akt-mTOR 和 NF-κB信号通路,并减弱心脏重塑. |
体内活性 | GKT137831可以预防人体主动脉内皮细胞对高血糖反应的氧化应激。GKT137831减弱HPAECs和HPASMCs中缺氧诱导的H2O2释放,细胞增殖和TGF-β1表达,并改善PPARγ表达减少。 |
激酶实验 | Kinase Assay: IC50 of tyrosine kinase activity is measured by an enzyme-linked immunosorbent assay (ELISA) with recombinant catalytic domains of a panel of receptor and non-receptor tyrosine kinases (in some cases only part of the catalytic domain is used). Saracatinib dose ranges from 0.001-10 mM. Speci?city assays against a panel of serine/threonine kinases are performed using a ?lter capture assay with 32P. Brie?y, multidrop 384 plates containing 0.5 μL Saracatinib or controls (DMSO) alone or pH 3.0 buffer controls) are incubated with 15 μL of enzyme plus peptide/protein substrate for 5 min before the reaction is initiated by the addition of 10 μL of 20 mM Mg-ATP. For all enzymes the ?nal concentration is approximated to the Michaelis constant (Km). Assays are carried out for 30min at room temperature before termination by the addition of 5 μL orthophosphoric acid. After mixing, the well contents are harvested onto a P81 Uni?lter plate, using orthophosphoric acid as the wash buffer. Then IC50 is calculated. |
细胞实验 | Hypoxic HPASMC and HPAEC proliferation is determined using MTT assay, by Western blotting to detect proliferating cell nuclear antigen (PCNA) expression, or by manual cell counting after Trypan blue staining. Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit is used to measure Water2 released into the culture media from HPAECs or HPASMCs. After exposure to control or hypoxic environments for 72 hours, Amplex Red reagent is added, and the cells are returned to control or hypoxic environments for an additional hour before fluorescence measurements. (Only for Reference) |
别名 | GKT137831 |
分子量 | 394.85 |
分子式 | C21H19ClN4O2 |
CAS No. | 1218942-37-0 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 72 mg/mL (182.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5326 mL | 12.663 mL | 25.3261 mL | 63.3152 mL |
5 mM | 0.5065 mL | 2.5326 mL | 5.0652 mL | 12.663 mL | |
10 mM | 0.2533 mL | 1.2663 mL | 2.5326 mL | 6.3315 mL | |
20 mM | 0.1266 mL | 0.6332 mL | 1.2663 mL | 3.1658 mL | |
50 mM | 0.0507 mL | 0.2533 mL | 0.5065 mL | 1.2663 mL | |
100 mM | 0.0253 mL | 0.1266 mL | 0.2533 mL | 0.6332 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Setanaxib 1218942-37-0 Apoptosis Immunology/Inflammation Metabolism NADPH-oxidase Ferroptosis NADPH GKT137831 NOX GKT-831 GKT831 inhibit GKT 831 GKT 137831 Inhibitor GKT-137831 NADPH Oxidase inhibitor